Lakefront Biotherapeutics | GLPG - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
argenx SE USD 4.3B 808.71M 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
Biogen USD 3.38B 374.2M 2026-03
Genmab DKK 1.72B 46M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
GRIFOLS EUR 801M 242.31M 2025-12
Hikma Pharmaceutical USD 236M 48M 2025-06
Incyte USD 4.02B 435.22M 2026-03
Merck EUR 2.33B 77M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
UCB EUR 1.57B 1.14B 2024-12
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03